S. Thayumanavan

Linker Chemistry in Antibody-Drug Conjugates: Current Strategies, Clinical Pharmacokinetic Analyses, and Linker-Free Outlooks.

This Viewpoint collects and discusses a plethora of linkers employed in ADC development, specifically focusing on advancements in antibody modification and linker cleavage chemistries.

Expanding the Repertoire of Lysosomal Degradation of Membrane Proteins: A Generalizable Strategy Using Multivalent Antibody−Polymer Chimeras

It is posited here that multivalent noncovalent interactions can trigger endosomal uptake and lysosomal degradation of specific membrane proteins in combination with an ancillary membrane protein, where the ancillary protein does not need to possess endogenous lysosome-directing characteristics.

Enzyme Activation of Triggerable Polymeric Lysosome Targeting Chimeras